COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00116896
Recruitment Status : Completed
First Posted : July 1, 2005
Last Update Posted : January 21, 2009
Information provided by:
OSI Pharmaceuticals

Brief Summary:
This is a Phase I, open-label, dose escalation, study of the combination of cisplatin and OSI-7904L given on Day 1 every 21 days in patient who have advanced solid tumors.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Drug: OSI-7904L Drug: Cisplatin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 25 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of OSI-7904L in Combination With Cisplatin in Patients With Advanced Solid Tumors
Study Start Date : June 2003
Study Completion Date : December 2004

Resource links provided by the National Library of Medicine

Drug Information available for: Cisplatin

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older
  • Advanced and/or metastatic solid tumor for which no effective therapy is available
  • ECOG performance status 0-2
  • Adequate bone marrow, hepatic and renal function

Exclusion Criteria:

  • Patients with active or uncontrolled infections
  • Neurotoxicity >= Grade 2
  • Symptomatic brain metastases which are not stable

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00116896

Layout table for location information
United States, Tennessee
Vanderbilt Universtiy Medical Center
Nashville, Tennessee, United States, 37232-6307
United States, Texas
Institute for Drug DevelopmentCancer Therapy & Research Center
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
OSI Pharmaceuticals
Layout table for additonal information Identifier: NCT00116896    
Other Study ID Numbers: OSI-904-102
First Posted: July 1, 2005    Key Record Dates
Last Update Posted: January 21, 2009
Last Verified: November 2003
Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents